Sumitomo Pharma Co Ltd (TSE:4506)
円 336 -19 (-5.35%) Market Cap: 133.49 Bil Enterprise Value: 516.24 Bil PE Ratio: 0 PB Ratio: 0.85 GF Score: 49/100

Q3 2022 Sumitomo Dainippon Pharma Co Ltd Earnings Call Transcript

Jan 31, 2022 / NTS GMT
Release Date Price: 円1246 (-1.11%)
Hisayoshi Kashima
Sumitomo Dainippon Pharma Co., Ltd. - Senior Director & Corporate Controller

My name is Hisayoshi Kashima. I would now like to report on our financial results for the third quarter of FY 2021 and the current status of clinical development based on the presentation materials.

Please see Page 3. We are pleased to report our financial results for the first 9 months of the fiscal year ending March 31, 2022. Revenues increased by JPY 37.3 billion or 9.5% year-on-year to JPY 432.1 billion. Sales increased in North America segment, which benefited from the recognition of $270 million in revenue from the upfront payment for the alliance with Otsuka Pharmaceutical, and in the China segment, which recovered from the impact of COVID-19. In Japan, sales decreased slightly due to the NHI price revision.

SG&A expenses increased due to the full-scale implementation of sales activities at Myovant Sciences and Urovant Sciences as well as an increase in amortization of intangible assets. R&D expenses decreased mainly in oncology and Myovant Sciences. As a result, core operating

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot